-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The new coronavirus mutant strain B.
1.
617 was first discovered in India at the end of 2020, so it is also called the Indian mutant strain.
After the mutant strain was discovered, it quickly spread to dozens of countries, including the United States, Singapore, and the United Kingdom, and has a tendency to become a major epidemic strain in some areas of these countries.
Moreover, in the Guangzhou epidemic, the B.
1.
617 variant has also been detected.
There are three subtypes of B.
1.
617 variants that have been identified: B.
1.
617.
1 (the "earliest" B.
1.
617), B.
1.
617.
2 and B.
1.
617.
3.
S gene testing and more detailed sequencing data of British virus samples show that B.
1.
617.
2 defeated the other two subtypes of B.
1.
617, and has the potential to replace B.
1.
1.
7, becoming a new wave of epidemics in the UK.
(B.
1.
1.
7, a variant strain found in southeast England at the end of 2020).
Julian Tang, a consultant virologist at the Royal Hospital of Leicester in the United Kingdom, believes that the B.
1.
617.
2 variant carries mutations named 452R and 478K.
Both of these mutations are related to increased infectivity and can change the use of the new coronavirus to invade Spike protein of human cells.
An analysis of British sequencing data shows that the daily increase in B.
1.
617.
2 infection cases may be 13% faster than that of B.
1.
1.
7.
A research report published on May 12 shows that according to existing data, B.
1.
617.
2 is 50% more infectious than B.
1.
1.
7, which is currently the strongest mutant strain.
Combing the mutation of new crown: ● D614G, discovered in February 2020, pandemic in June 2020.
● B.
1.
1.
207, discovered in Nigeria, Africa in August 2020, the transmission capacity of this mutant strain has not been significantly improved. ● 501Y.
V2/B.
1.
351, the South African mutation, was discovered in October 2020.
There are 8 mutations in the spike protein, which has a very strong transmission ability and will become a pandemic soon.
Even this mutation is used in Pfizer and Moderna vaccines.
Harmony is increased by 20-40 times.
The good news is that the domestic recombinant protein subunit COVID-19 vaccine (developed by Zhifei Biology and the Institute of Microbiology, Chinese Academy of Sciences) and the domestically approved inactivated COVID-19 vaccine (Beijing Institute of Biological Products) still have a protective effect on the new variants in South Africa.
● B.
1.
1.
7 (501Y.
V1), discovered in October 2020, and dominated in London and South East England in less than three months.
Subsequent modeling work estimates that the transmission rate of B.
1.
1.
7 has increased by about 50%, which may cause the average number of infected persons to spread the virus between 0.
4 and 0.
7.
The analysis of 17,000 cases showed that the B.
1.
1.
7 mutant strain increased the risk of death by 61%.
As of January 11, 2021, B.
1.
1.
7 mutations have been detected in 49 countries, including many countries in Europe, Asia, and the Americas.
B.
1.
1.
7 Mutant strains can be neutralized by vaccine-induced antibodies.
● B.
1.
429, discovered in the United States in November 2020, this mutant strain consists of five different mutations, three of which (S13I, W152C, L452R) are in the S protein of the virus.
By the end of February 2021, the proportion of this mutant strain has accounted for a staggering 48%, and has been found in at least more than 40 states and 20 countries.
The 452R mutation reduces the sensitivity of neutralizing antibodies by at least 4-fold.
● B.
1.
526, discovered in New York, accounts for about a quarter of the virus sequences appearing in the database shared by scientists.
● P.
1 and P.
2 were discovered in January 2021 and confirmed as immune escape mutants.
Up to 60% of patients can be infected by P.
1 for the second time (preliminary data not yet officially published). The neutralization of P.
1 and P.
2 anti-Pfizer and Moderna vaccine vaccines increased by 5 to 7 times.
It is gratifying that foreign media reported on March 11 that China Kexing’s new crown vaccine is initially effective against P.
1 and P.
2 mutant strains of new coronavirus.
● B.
1.
617, the Indian mutant strain, was first discovered at the end of 2020, followed by a pandemic soon, and has a tendency to become the main epidemic strain.
Virus mutations and immune escape are common problems in academia.
When a virus infects a cell, a series of viral proteins are expressed in the infected cell, and their proteins are processed by human leukocyte antigen (HLA-I) and displayed on the surface of the host cell.
This combination (HLA-I+peptide) on the surface of the host cell is recognized by the circulating cytotoxic T cells (CTL) (bound to the TCR), and the CTL initiates an immune response to eliminate the infected cells.
Therefore, studying the HLA-I peptide sequence derived from SARS-CoV-2 will help identify viral epitopes related to cytotoxic T cell activation, and then provide some new ideas for antiviral therapy research and vaccine research.
On May 27, 2021, Cell Journal published an online report by the Pardis Sabeti team from the Broad Institute of MIT and Harvard University, titled: Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs research paper.
The paper showed that after SARS-CoV-2 infection, about 25% of the SARS-CoV-2 HLA-I peptide group presented antigenic peptides other than non-classical ORF, and suggested that in the face of mutant strains, in the next generation In vaccines, the integration of T cell antigen peptides into the design is hopeful for long-term protection.
Because the early research mainly focused on structural proteins, and the current post-infection inspection or vaccine design is equivalent to directly excluding the 1/4 important source of antigen peptides.
The author hopes that its research conclusions will help the further iteration of the vaccine.
The various antigen peptides presented came from non-classical ORFs Jiman Biotechnology (Shanghai) Co.
, Ltd.
, a high-tech enterprise specializing in the research and development of cutting-edge biotechnology technologies.
Since its establishment 9 years ago, the company has been committed to the development and application of gene delivery vectors such as lentivirus and AAV, and has rich experience in virus packaging and modification.
Since the outbreak of the new crown, the company urgently established a research and development team to assist in research related to the new crown, and developed nearly 40 mutant S protein pseudoviruses, recombinant biotinylated human ACE2 protein (Biotinylated Human ACE2 Protein), and new coronavirus synaptic protein (SARS).
-Cov-2 Spike Protein RBD), and a series of products such as COVID-19 neutralizing antibody detection kits, providing complete solutions for COVID-19 related research.
The new coronavirus-related pseudovirus developed by Jiman Biologics carries both GFP and Luciferase labels.
GFP green fluorescence observation is more intuitive, and Luciferase meets both the sensitivity and quantitative requirements.
1.
ACE2 protein (Biotinylated Human ACE2 Protein) 2.
New coronavirus synaptic protein (SARS-Cov-2 Spike Protein RBD) 3.
New coronavirus neutralizing antibody detection kit 4.
SARS-CoV-2 S protein neutralizing antibody pseudovirus Spot 5.
ACE2 overexpression cell line spot 6.
Neutralizing antibody detection service Human ACE2 Protein, recombinant biotinylated human ACE2 protein related data display SARS-CoV-2 Spike RBD Protein, SARS-CoV-2 Spike RBD protein new crown pseudovirus Neutralizing antibody-related data display new coronavirus-related protein products and neutralizing antibody detection kits, new coronavirus pseudovirus (can be used for neutralizing antibody effect evaluation) related overexpression cell lines, welcome to consult: 18916119826 (same number on WeChat)
1.
617 was first discovered in India at the end of 2020, so it is also called the Indian mutant strain.
After the mutant strain was discovered, it quickly spread to dozens of countries, including the United States, Singapore, and the United Kingdom, and has a tendency to become a major epidemic strain in some areas of these countries.
Moreover, in the Guangzhou epidemic, the B.
1.
617 variant has also been detected.
There are three subtypes of B.
1.
617 variants that have been identified: B.
1.
617.
1 (the "earliest" B.
1.
617), B.
1.
617.
2 and B.
1.
617.
3.
S gene testing and more detailed sequencing data of British virus samples show that B.
1.
617.
2 defeated the other two subtypes of B.
1.
617, and has the potential to replace B.
1.
1.
7, becoming a new wave of epidemics in the UK.
(B.
1.
1.
7, a variant strain found in southeast England at the end of 2020).
Julian Tang, a consultant virologist at the Royal Hospital of Leicester in the United Kingdom, believes that the B.
1.
617.
2 variant carries mutations named 452R and 478K.
Both of these mutations are related to increased infectivity and can change the use of the new coronavirus to invade Spike protein of human cells.
An analysis of British sequencing data shows that the daily increase in B.
1.
617.
2 infection cases may be 13% faster than that of B.
1.
1.
7.
A research report published on May 12 shows that according to existing data, B.
1.
617.
2 is 50% more infectious than B.
1.
1.
7, which is currently the strongest mutant strain.
Combing the mutation of new crown: ● D614G, discovered in February 2020, pandemic in June 2020.
● B.
1.
1.
207, discovered in Nigeria, Africa in August 2020, the transmission capacity of this mutant strain has not been significantly improved. ● 501Y.
V2/B.
1.
351, the South African mutation, was discovered in October 2020.
There are 8 mutations in the spike protein, which has a very strong transmission ability and will become a pandemic soon.
Even this mutation is used in Pfizer and Moderna vaccines.
Harmony is increased by 20-40 times.
The good news is that the domestic recombinant protein subunit COVID-19 vaccine (developed by Zhifei Biology and the Institute of Microbiology, Chinese Academy of Sciences) and the domestically approved inactivated COVID-19 vaccine (Beijing Institute of Biological Products) still have a protective effect on the new variants in South Africa.
● B.
1.
1.
7 (501Y.
V1), discovered in October 2020, and dominated in London and South East England in less than three months.
Subsequent modeling work estimates that the transmission rate of B.
1.
1.
7 has increased by about 50%, which may cause the average number of infected persons to spread the virus between 0.
4 and 0.
7.
The analysis of 17,000 cases showed that the B.
1.
1.
7 mutant strain increased the risk of death by 61%.
As of January 11, 2021, B.
1.
1.
7 mutations have been detected in 49 countries, including many countries in Europe, Asia, and the Americas.
B.
1.
1.
7 Mutant strains can be neutralized by vaccine-induced antibodies.
● B.
1.
429, discovered in the United States in November 2020, this mutant strain consists of five different mutations, three of which (S13I, W152C, L452R) are in the S protein of the virus.
By the end of February 2021, the proportion of this mutant strain has accounted for a staggering 48%, and has been found in at least more than 40 states and 20 countries.
The 452R mutation reduces the sensitivity of neutralizing antibodies by at least 4-fold.
● B.
1.
526, discovered in New York, accounts for about a quarter of the virus sequences appearing in the database shared by scientists.
● P.
1 and P.
2 were discovered in January 2021 and confirmed as immune escape mutants.
Up to 60% of patients can be infected by P.
1 for the second time (preliminary data not yet officially published). The neutralization of P.
1 and P.
2 anti-Pfizer and Moderna vaccine vaccines increased by 5 to 7 times.
It is gratifying that foreign media reported on March 11 that China Kexing’s new crown vaccine is initially effective against P.
1 and P.
2 mutant strains of new coronavirus.
● B.
1.
617, the Indian mutant strain, was first discovered at the end of 2020, followed by a pandemic soon, and has a tendency to become the main epidemic strain.
Virus mutations and immune escape are common problems in academia.
When a virus infects a cell, a series of viral proteins are expressed in the infected cell, and their proteins are processed by human leukocyte antigen (HLA-I) and displayed on the surface of the host cell.
This combination (HLA-I+peptide) on the surface of the host cell is recognized by the circulating cytotoxic T cells (CTL) (bound to the TCR), and the CTL initiates an immune response to eliminate the infected cells.
Therefore, studying the HLA-I peptide sequence derived from SARS-CoV-2 will help identify viral epitopes related to cytotoxic T cell activation, and then provide some new ideas for antiviral therapy research and vaccine research.
On May 27, 2021, Cell Journal published an online report by the Pardis Sabeti team from the Broad Institute of MIT and Harvard University, titled: Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs research paper.
The paper showed that after SARS-CoV-2 infection, about 25% of the SARS-CoV-2 HLA-I peptide group presented antigenic peptides other than non-classical ORF, and suggested that in the face of mutant strains, in the next generation In vaccines, the integration of T cell antigen peptides into the design is hopeful for long-term protection.
Because the early research mainly focused on structural proteins, and the current post-infection inspection or vaccine design is equivalent to directly excluding the 1/4 important source of antigen peptides.
The author hopes that its research conclusions will help the further iteration of the vaccine.
The various antigen peptides presented came from non-classical ORFs Jiman Biotechnology (Shanghai) Co.
, Ltd.
, a high-tech enterprise specializing in the research and development of cutting-edge biotechnology technologies.
Since its establishment 9 years ago, the company has been committed to the development and application of gene delivery vectors such as lentivirus and AAV, and has rich experience in virus packaging and modification.
Since the outbreak of the new crown, the company urgently established a research and development team to assist in research related to the new crown, and developed nearly 40 mutant S protein pseudoviruses, recombinant biotinylated human ACE2 protein (Biotinylated Human ACE2 Protein), and new coronavirus synaptic protein (SARS).
-Cov-2 Spike Protein RBD), and a series of products such as COVID-19 neutralizing antibody detection kits, providing complete solutions for COVID-19 related research.
The new coronavirus-related pseudovirus developed by Jiman Biologics carries both GFP and Luciferase labels.
GFP green fluorescence observation is more intuitive, and Luciferase meets both the sensitivity and quantitative requirements.
1.
ACE2 protein (Biotinylated Human ACE2 Protein) 2.
New coronavirus synaptic protein (SARS-Cov-2 Spike Protein RBD) 3.
New coronavirus neutralizing antibody detection kit 4.
SARS-CoV-2 S protein neutralizing antibody pseudovirus Spot 5.
ACE2 overexpression cell line spot 6.
Neutralizing antibody detection service Human ACE2 Protein, recombinant biotinylated human ACE2 protein related data display SARS-CoV-2 Spike RBD Protein, SARS-CoV-2 Spike RBD protein new crown pseudovirus Neutralizing antibody-related data display new coronavirus-related protein products and neutralizing antibody detection kits, new coronavirus pseudovirus (can be used for neutralizing antibody effect evaluation) related overexpression cell lines, welcome to consult: 18916119826 (same number on WeChat)
